Cdc2-related kinase 6 (CRK6)

Cdc2-related kinase 6 (CRK6) is a protein kinase expressed by the protozoan parasite Leishmania donovani, the primary causative agent of visceral leishmaniasis (NIH, 2017). As a member of the CMGC kinase family and a homolog of mammalian cyclin-dependent kinases (CDKs), CRK6 is involved in the regulation of the parasite's cell cycle and signal transduction pathways (PubMed, 2021). While its exact biological role in Leishmania is less defined than that of other kinases like CRK3 or CRK12, it is known to be part of the machinery that governs parasite proliferation and differentiation between life stages (NIH, 2020). CRK6 has gained attention as a potential therapeutic target because it binds to the pyrazolopyrimidine class of anti-leishmanial drugs, including the preclinical candidate GSK3186899, also known as DDD853651 (NIH, 2017). Although CRK12 is considered the primary target of these compounds, the interaction with CRK6 suggests it may contribute to the overall efficacy of kinase-inhibiting therapies through polypharmacological effects (PubMed, 2017). Targeting CRK6 represents a strategy to exploit the differences between parasite and host cell cycle machinery for therapeutic intervention (NIH, 2021). The development of selective inhibitors for CRK6 is crucial to avoid cross-reactivity with human CDKs and minimize side effects (PubMed, 2020). Ongoing research into CRK6 continues to elucidate the unique signaling pathways required for successful intracellular parasitism (NIH, 2020).

Other names

CRK6LdCRK6Putative cdc2-related kinase 6LdCL_270010500

Inhibition of kinase activity through ATP-competitive binding, leading to cell cycle arrest.